Infusion reactions and their management

Mayer, Lloyd; Young, Yuki

doi:10.1016/j.gtc.2006.09.006

Cited by 54 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34 Most frequently, these are characterized by mild erythema, injection-site redness, flushing, or urticarial rash that resolves on reduction of infusion rate and systemic administration of steroids and/or antihistamines. However, cases of severe desquamating skin reactions, such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have also been described with infliximab (IFX) and adalimumab (ADA).…”

Section: Adverse Skin Reactions Induced By Anti-tnf Therapymentioning

confidence: 99%

Skin Side Effects of Inflammatory Bowel Disease Therapy

Torres

Buche

Delaporte

et al. 2013

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Skin manifestations are common in patients suffering from inflammatory bowel disease (IBD) and can be associated with the disease itself, with nutritional deficiencies, or with therapy. All drugs currently used for treating IBD have the potential to cause dermatologic manifestations that can have a wide range of clinical presentations, from mild drug eruptions to potentially life-threatening immune-mediated reactions. The wider use of thiopurines and anti-tumor necrosis factor in the past years has led to the recognition of 2 more skin complications of IBD therapy: the potentially disfiguring non-melanoma skin cancer associated with the current or past use of thiopurines and the paradoxical new onset or exacerbation of anti-tumor necrosis factor-associated psoriasis. Despite being rare, these complications can be severe and lead to therapy discontinuation, and therefore, gastroenterologists need to become familiar with their epidemiology, diagnosis, and management. Herein, we reviewed the skin side effects of IBD therapy, specially focusing in thiopurines and anti-tumor necrosis factor therapy and in the recently described skin cancer and psoriasis, and we tried to advance some practical algorithms that can provide some help to the clinicians dealing with these complications in their day-by-day practice.

show abstract

Section: Adverse Skin Reactions Induced By Anti-tnf Therapymentioning

confidence: 99%

Skin Side Effects of Inflammatory Bowel Disease Therapy

Torres

Buche

Delaporte

et al. 2013

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Anti-drug antibodies (ADA) have been implicated in infusion reactions and anaphylaxis (6,7) as well as immune complex-mediated diseases (8,9). ADA have also caused secondary treatment failures (loss of efficacy) (10)(11)(12) and, in rare occasions, more serious adverse events such as deficiency syndromes for instance thrombocytopenia and pure red cell aplasia (13,14).…”

Section: Introductionmentioning

confidence: 99%

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations

Shankar

Arkin

Cocea

et al. 2014

AAPS J

255

264

View full text Add to dashboard Cite

Abstract. Immunogenicity is a significant concern for biologic drugs as it can affect both safety and efficacy. To date, the descriptions of product immunogenicity have varied not only due to different degrees of understanding of product immunogenicity at the time of licensing but also due to an evolving lexicon that has generated some confusion in the field. In recent years, there has been growing consensus regarding the data needed to assess product immunogenicity. Harmonization of the strategy for the elucidation of product immunogenicity by drug developers, as well as the use of defined common terminology, can benefit medical practitioners, health regulatory agencies, and ultimately the patients. Clearly, understanding the incidence, kinetics and magnitude of anti-drug antibody (ADA), its neutralizing ability, cross-reactivity with endogenous molecules or other marketed biologic drugs, and related clinical impact may enhance clinical management of patients treated with biologic drugs. To that end, the authors present terms and definitions for describing and analyzing clinical immunogenicity data and suggest approaches to data presentation, emphasizing associations of ADA development with pharmacokinetics, efficacy, and safety that are necessary to assess the clinical relevance of immunogenicity.

show abstract

“…However, the prevention of antibody development did not produce a decrease in adverse events. In a review, Mayer and Young also suggested that infusion reactions might be related to the presence of these antibodies 10. These studies were trying to imply that the acute adverse reactions might be allergic in nature.…”

Section: Discussionmentioning

confidence: 99%

Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions

Ducharme

Pelletier²,

Zacharias³

2011

Frontline Gastroenterol

View full text Add to dashboard Cite

Objective The purpose of this study was to identify the association of premedication with the adverse drug reaction (ADR) rate in infl iximab infusions. Design A retrospective chart review of 684 patients who received 4077 infusions in a network of community clinics over 16.5 months. Data collected included age, weight, sex, diagnosis, dose, premedications and ADR information, which was coded for time of onset, severity and outcome.

show abstract

Infusion reactions and their management

Cited by 54 publications

References 13 publications

Skin Side Effects of Inflammatory Bowel Disease Therapy

Skin Side Effects of Inflammatory Bowel Disease Therapy

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations

Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions

Contact Info

Product

Resources

About